A detailed history of Macquarie Group LTD transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 899,999 shares of CHRS stock, worth $1.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
899,999
Previous 899,999 -0.0%
Holding current value
$1.41 Million
Previous $1.56 Million 39.91%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$2.02 - $3.14 $505,000 - $785,000
250,000 Added 38.46%
899,999 $2.15 Million
Q4 2023

Feb 14, 2024

BUY
$1.59 - $3.85 $240,726 - $582,890
151,400 Added 30.37%
649,999 $2.16 Million
Q3 2023

Nov 14, 2023

BUY
$3.74 - $5.45 $256,560 - $373,864
68,599 Added 15.95%
498,599 $1.86 Million
Q4 2022

Feb 21, 2023

SELL
$5.69 - $10.07 $3,362 - $5,951
-591 Reduced 0.14%
430,000 $3.41 Million
Q3 2022

Nov 14, 2022

SELL
$7.17 - $13.87 $5,621 - $10,874
-784 Reduced 0.18%
430,591 $4.15 Million
Q1 2021

May 14, 2021

SELL
$14.42 - $21.39 $5,349 - $7,935
-371 Reduced 0.09%
431,375 $6.3 Million
Q2 2020

Aug 11, 2020

BUY
$14.43 - $19.16 $25,194 - $33,453
1,746 Added 0.41%
431,746 $7.71 Million
Q1 2019

May 15, 2019

SELL
$8.38 - $15.5 $2,514 - $4,650
-300 Reduced 0.07%
430,000 $5.87 Million
Q3 2018

Nov 15, 2018

SELL
$14.45 - $20.25 $39,015 - $54,675
-2,700 Reduced 0.62%
430,300 $7.1 Million
Q2 2018

Aug 14, 2018

BUY
$10.25 - $17.45 $133,250 - $226,850
13,000 Added 3.1%
433,000 $6.06 Million
Q1 2018

May 11, 2018

BUY
$9.1 - $13.7 $215,670 - $324,690
23,700 Added 5.98%
420,000 $4.64 Million
Q4 2017

Feb 15, 2018

BUY
$8.35 - $14.4 $887,605 - $1.53 Million
106,300 Added 36.66%
396,300 $3.49 Million
Q3 2017

Nov 08, 2017

BUY
$11.1 - $14.5 $3.22 Million - $4.21 Million
290,000
290,000 $3.87 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $122M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.